IPOs on deck

Two biotechs look poised to make exits this week, including infectious disease company Trius Therapeutics Inc., which is anticipated to price its IPO on Tuesday, and NuPathe Inc., a neurology play expected to price at some point during the week.

Trius plans to sell 6 million shares at $12-$14 through underwriters Citigroup; Piper Jaffray; Canaccord; and JMP Securities. At the mid-point, Trius would raise $78 million and have a post-money valuation of $216.8 million...